Skip to main content
. 2013 Feb 28;19(8):1318–1321. doi: 10.3748/wjg.v19.i8.1318

Figure 1.

Figure 1

Clinical course of cases. A: Case 1, showing alanine transaminase (ALT) and Bcr-Abl/AblIS ratio over time; B: Case 2, showing ALT and Bcr-Abl/AblIS ratio over time; C: Case 3, showing ALT and Bcr-Abl/AblIS ratio over time. IM: Imatinib mesylate; IS: International scale.